These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28971631)

  • 1. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.
    Singh SR; Dogra A; Stewart M; Das T; Chhablani J
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):561-568. PubMed ID: 28971631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziv-aflibercept in macular disease.
    Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
    Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziv-aflibercept for Better Regulating Neovascular Age-Related Macular Degeneration (ZEBRA): A Prospective, Randomized Trial.
    D'Souza HS; Kapoor KG; Wagner AL
    Semin Ophthalmol; 2021 Feb; 36(1-2):28-34. PubMed ID: 33577373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziv-aflibercept: A cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor.
    Mansour AM; Stewart MW; Farah ME; Mansour HA; Chhablani J
    Acta Ophthalmol; 2020 Aug; 98(5):e540-e548. PubMed ID: 31863550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT.
    Chhablani J; Narayanan R; Mathai A; Yogi R; Stewart M
    Retina; 2016 Jun; 36(6):1126-31. PubMed ID: 26655620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Ziv-Aflibercept: A Comprehensive Review.
    Barmas-Alamdari D; D'Souza HS; Kapoor KG; Wagner AL
    Semin Ophthalmol; 2019; 34(6):420-435. PubMed ID: 31314638
    [No Abstract]   [Full Text] [Related]  

  • 9. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
    de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
    Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
    Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept: an update on recent milestones achieved.
    Palejwala NV; Lauer AK
    Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration.
    Ayachit A; Singh SR; Subramanyam A; Tiwari S; Heranjal A; Chattannavar G; Pandey P; Salti H; Mansour MA; Mansour A; Chhablani J
    Asia Pac J Ophthalmol (Phila); 2020; 9(2):144-148. PubMed ID: 32175924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
    Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
    Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
    Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of 5914 intravitreal ziv-aflibercept injections.
    Singh SR; Stewart MW; Chattannavar G; Ashraf M; Souka A; ElDardeery M; Wadhwa N; Sarvaiya C; Mansour AM; Marashi A; Ramchandani S; Braimah IZ; Jabbarpoor Bonyadi MH; Ramezani A; Soheilian M; de Oliveira Dias JR; de Andrade GC; Maia A; Rodrigues EB; Farah ME; Banker A; Chhablani J;
    Br J Ophthalmol; 2019 Jun; 103(6):805-810. PubMed ID: 30099379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT.
    Yogi R; Stewart M; Chhablani J
    Retin Cases Brief Rep; 2017 Spring; 11(2):111-113. PubMed ID: 27078613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.